Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing antibody complement therapeutics for severe autoimmune diseases, has announced its upcoming participation in two major investor conferences in February 2025.
The company's CEO, Marino Garcia, will present at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET, which will be held virtually.
Interested parties can access live webcasts of both presentations through the 'News and Events' section of the Investors page on Dianthus Therapeutics' website.
Dianthus Therapeutics (Nasdaq: DNTH), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di terapie a base di anticorpi per gravi malattie autoimmuni, ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori a febbraio 2025.
Il CEO dell'azienda, Marino Garcia, presenterà alla Guggenheim SMID Cap Biotech Conference il 6 febbraio alle 9:00 ET a New York City, e alla Oppenheimer 35th Annual Healthcare Life Sciences Conference il 12 febbraio alle 15:20 ET, che si svolgerà virtualmente.
Le parti interessate possono accedere alle trasmissioni in diretta di entrambe le presentazioni attraverso la sezione 'News and Events' della pagina Investitori sul sito web di Dianthus Therapeutics.
Dianthus Therapeutics (Nasdaq: DNTH), una compañía biotecnológica en etapa clínica centrada en el desarrollo de terapias anticuerpos para enfermedades autoinmunes severas, ha anunciado su próxima participación en dos importantes conferencias para inversores en febrero de 2025.
El CEO de la empresa, Marino Garcia, presentará en la Guggenheim SMID Cap Biotech Conference el 6 de febrero a las 9:00 a.m. ET en Nueva York, y en la Oppenheimer 35th Annual Healthcare Life Sciences Conference el 12 de febrero a las 3:20 p.m. ET, que se llevará a cabo de manera virtual.
Las partes interesadas pueden acceder a las transmisiones en vivo de ambas presentaciones a través de la sección 'News and Events' en la página para inversores del sitio web de Dianthus Therapeutics.
디안투스 테라퓨틱스(Dianthus Therapeutics, 나스닥: DNTH)는 중증 자가면역 질환을 위한 항체 보완 치료제 개발에 집중하는 임상 단계의 생명공학 회사로, 2025년 2월에 열리는 두 개의 주요 투자자 회의에 참석할 예정입니다.
회사의 CEO인 마리노 가르시아(Marino Garcia)는 2월 6일 오전 9시(동부 표준시)에 뉴욕에서 열리는 구겐하임 SMID 캡 생명공학 회의(Guggenheim SMID Cap Biotech Conference)와 2월 12일 오후 3시 20분(동부 표준시)에 온라인으로 진행되는 오펜하이머 제35회 연례 헬스케어 생명과학 회의(Oppenheimer 35th Annual Healthcare Life Sciences Conference)에서 발표할 예정입니다.
관심 있는 분들은 디안투스 테라퓨틱스 웹사이트의 '뉴스 및 행사(News and Events)' 섹션을 통해 두 발표의 실시간 웹캐스트에 접속할 수 있습니다.
Dianthus Therapeutics (Nasdaq: DNTH), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies par anticorps pour des maladies auto-immunes graves, a annoncé sa prochaine participation à deux grandes conférences d'investisseurs en février 2025.
Le PDG de la société, Marino Garcia, présentera à la Guggenheim SMID Cap Biotech Conference le 6 février à 9h00 ET à New York, et à la Conférence annuelle sur les sciences de la vie de santé Oppenheimer le 12 février à 15h20 ET, qui se tiendra virtuellement.
Les parties intéressées peuvent accéder aux webinaires en direct des deux présentations via la section 'Actualités et événements' de la page Investisseurs du site web de Dianthus Therapeutics.
Dianthus Therapeutics (Nasdaq: DNTH), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-Therapeutika für schwere Autoimmunerkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen im Februar 2025 angekündigt.
Der CEO des Unternehmens, Marino Garcia, wird am 6. Februar um 9:00 Uhr ET in New York City auf der Guggenheim SMID Cap Biotech Conference und am 12. Februar um 15:20 Uhr ET, die virtuell abgehalten wird, auf der Oppenheimer 35. Jahrestagung für Gesundheitswissenschaften präsentieren.
Interessierte Parteien können über den Bereich 'Nachrichten und Veranstaltungen' auf der Investoren-Seite der Website von Dianthus Therapeutics auf die Live-Übertragungen beider Präsentationen zugreifen.
- None.
- None.
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:
- Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York City
- Oppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET, taking place virtually
Live webcasts of the Company’s presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ
When and where will Dianthus Therapeutics (DNTH) present at the Guggenheim SMID Cap Biotech Conference?
What time is Dianthus Therapeutics' (DNTH) presentation at the Oppenheimer Healthcare Conference?
How can investors access Dianthus Therapeutics' (DNTH) February 2025 conference presentations?